Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06743100 | 18F-Floretyrosine Expanded Access Program | no longer available | — | — | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT04802447 | SurVaxM Expanded Access Protocol(EAP) | no longer available | — | — | Roswell Park Cancer InstituteOTHER | 0 | Sep 16, 2025 |
| NCT05518838 | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | no longer available | — | — | Oblato, Inc.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05936216 | TVI-Brain-1 in Expanded Access Patient | no longer available | — | — | TVAX BiomedicalINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05551013 | Treatment of Recurrent GBM With APG-157 Via Expanded Access | no longer available | — | — | Aveta Biomics, Inc.INDUSTRY | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06439849 | Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma(TRIANGLE) | no longer available | — | — | Petrov, AndreyOTHER | 0 | Jul 16, 2024 | clinicaltrials |
| NCT04321694 | Expanded Access for KHK2455 | no longer available | — | — | Kyowa Kirin, Inc.INDUSTRY | 0 | Apr 25, 2024 | clinicaltrials |
| NCT04599647 | EAP for the Treatment of Glioblastoma With PVSRIPO | no longer available | — | — | Istari Oncology, Inc.INDUSTRY | 1 | Jun 29, 2022 | clinicaltrials |
| NCT05392374 | Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas | no longer available | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT03134131 | Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas | no longer available | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | no longer available | — | — | Center Trials & TreatmentOTHER | 8 | Nov 8, 2019 | clinicaltrials |
| NCT03123952 | Expanded Access to ABT-414 | no longer available | — | — | AbbVieINDUSTRY | 0 | Jul 15, 2019 | clinicaltrials |
| NCT03311542 | Expanded Access for Pembrolizumab (MK-3475) | no longer available | — | — | Center Trials & TreatmentOTHER | 4 | Jan 10, 2018 | clinicaltrials |
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut(CDX-110) | no longer available | — | — | Celldex TherapeuticsINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT02755987 | Expanded Access to ANG1005 for Individual Patients | no longer available | — | — | Angiochem IncINDUSTRY | 1 | Jun 7, 2016 | clinicaltrials |
Data updated 22 days agoSource updated May 29, 2026source: clinicaltrials